Schroeder Mark S

Mark S. Schroeder (EVP, Pres Diagnostics & COO) sold 2,635 shares of LH at $231.67; stock down 7.3% in 30 days post-sale.

Schroeder sold 2,635 shares (34.7% of his pre-transaction holding of 7,595 shares) at $231.67 on 2025-03-28, reducing his position from 7.6K to 5.0K shares. The stock has declined 7.3% over the subsequent 30 days and trades 9.4% below its 52-week high of $256.81. His same-ticker trade history at LH shows 3 prior measurable 90-day outcomes, all negative: −13.8%, −9.4%, and −6.3%, consistent with a pattern of well-timed exit execution. His cross-ticker track record shows 4 prior sells with an average 90-day return of −8.1% and a 100.00% well-timed rate, indicating his open-market sales have historically preceded declines. The company's fundamentals remain solid (7.0% annual revenue growth, P/E 25.52, $3.3B quarterly revenue), but the consistent post-sale price weakness in this insider's history warrants attention as a potential technical or fundamental headwind signal.

EVP Mark Schroeder sold 5,339 shares of LH at $249.23 (-51.8% of holdings); all 3 prior LH sales were well-timed at 90-day mark

Mark Schroeder, Executive Vice President and President of Diagnostics & COO at LabCorp, sold 5,339 shares at $249.23 on 2025-02-28, reducing his holdings from 10,299 to 4,960 shares. This represents a -51.8% reduction in his position, a material reduction in ownership stake. Schroeder has a demonstrated track record at this specific ticker: his 3 prior open-market sales at LH were all well-timed, with negative 90-day returns ranging from -6.3% to -9.4%, meaning the stock declined after each sale. His cross-ticker track record shows a 100.00% well-timed rate on sells with an average 90-day return of -8.1%, indicating consistent discipline in timing exits. The stock is currently trading at $256.81, near the 52-week high of $256.81, suggesting this sale occurred during a period of elevated valuation relative to recent price action.